Iterum Therapeutics Receives QIDP for Oral and IV Sulopenem in Four Additional Indications as well as Fast Track Designation
DUBLIN, Ireland and CHICAGO, March 19, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant pathogens, today announced that the U.S. Food and Drug …